Specialty Pharma Journal Specialty, Precision & Technology
BOSTON, Mass.–(BUSINESS WIRE)–Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced a collaboration with The Leukemia & Lymphoma Society® (LLS), to accelerate the development of duvelisib for the treatment of patients …
Tag Archives: non-hodgkin lymphoma
November, 2018
September, 2018
-
25 September
FDA Lifts Clinical Hold on Epizyme’s Tazemetostat Program in Follicular Lymphoma
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials. Epizyme is now in the process of reopening enrollment …
July, 2018
-
10 July
CTI BioPharma’s Pixurvi Fails to Meet Primary Endpoint in Phase 3 Non-Hodgkin Lymphoma Trial
PARIS–(BUSINESS WIRE)–CTI BioPharma Corp. and Servier today announced that the pivotal Phase III study (PIX306) evaluating PIXUVRI® (pixantrone) combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) did not meet its primary endpoint of improvement of progression-free survival (PFS). “We are …
December, 2017
-
11 December
Juno Therapeutics and Celgene Release Additional Data from its Trial of JCAR017 in Aggressive B-Cell NHL
SEATTLE & SUMMIT, N.J.–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, and Celgene Corporation (NASDAQ: CELG) today released additional data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma …
August, 2017
-
3 August
Kite Announces Publication of Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma Outcomes
SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today highlighted the publication of the first large-scale multi-institutional analysis of outcomes of patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the latest electronic edition of BLOOD. The study, SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research), showed outcomes in patients with refractory aggressive …
June, 2017
-
5 June
Juno Therapeutics Presents Updated Results for its CAR-T Candidate in Aggressive NHL
SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated data from the TRANSCEND trial of JCAR017 in relapsed and refractory (r/r) aggressive B cell non-Hodgkin lymphoma (NHL) in a presentation at the 2017 Annual Meeting of the American …
May, 2017
-
30 May
FDA Grants Priority Review to Kite Pharma’s Non-Hodgkin Lymphoma Drug
SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for axicabtagene ciloleucel. The submission follows positive data demonstrated with a single infusion of axicabtagene ciloleucel in the …
April, 2017
-
3 April
Kite Completes FDA Filing of its CAR-T Therapy for Aggressive Non-Hodgkin Lymphoma
SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has completed the rolling submission with the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) for axicabtagene ciloleucel (previously known as KTE-C19) as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) …
February, 2017
-
28 February
Kite Pharma’s CAR-T Therapy Meets Primary Endpoint in Pivotal Trial in Patients with Non-Hodgkin Lymphoma
SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc., (Nasdaq:KITE) today announced positive data from the primary analysis of ZUMA-1 for its lead CAR-T candidate, axicabtagene ciloleucel (previously referred to as KTE-C19), in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma (NHL). The study met the primary endpoint of objective response rate (ORR), or …
December, 2016
-
5 December
Kite Pharma Initiates Rolling BLA Submission for CAR-T Therapy KTE-C19 in NHL
SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has initiated the rolling submission with the U.S. Food and Drug Administration (FDA) of the Biologics License Application (BLA) for KTE-C19 as a treatment for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who are ineligible for autologous stem …